Edward Tenthoff
Edward Tenthoff
companies discovery earnings four growth investors leaves looking product wait
Investors will be looking at companies with earnings and growth potential. They're not going to wait two years for drug discovery and four years for product development. And that leaves a lot of biotech companies off the radar.
line pipes starting
They are at the starting line now. They have all the bioreactors in there. The pipes are connected. All the switches work. Now they have to get clearance.
timing
The timing of this announcement is very, very fortuitous.
data drives home primarily
If the once-a-month data were equivalent, it would have been a home run. Efficacy is what primarily drives the hepatitis C market.
faster generate revenue
Typically, they are faster to generate revenue and, hopefully, faster to profitability.